Considering the important role of Ara-C in AML treatment and the important advantages of HFn in targeted drug delivery (such as good biosafety and ease of expression and purification), the above analysis results encouraged us to further analyze whether TFRC expression was downregulated in AML cells post Ara-C treatment based on the GEO database. Here, TFRC is linked to acute myeloid leukemia.